Clinical trialNCT03345979CompletedPhase 3Interventional

A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia

SponsorAlkermes, Inc.Enrollment200Schizophrenia

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study will evaluate the efficacy of initiating treatment of schizophrenia with ARISTADA INITIO plus 30 mg oral aripiprazole followed by a 2-month dose of AL.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Sanjeev Pathak, MD
Alkermes, Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

16 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Alkermes Investigational Site
Little Rock, Arkansas, United States
Alkermes Investigational Site
Rogers, Arkansas, United States
Alkermes Investigational Site
Cerritos, California, United States
Alkermes Investigational Site
Culver City, California, United States
Alkermes Investigational Site
Garden Grove, California, United States
Alkermes Investigational Site
Lemon Grove, California, United States
Alkermes Investigational Site
Hialeah, Florida, United States
Alkermes Investigational Site
Chicago, Illinois, United States
Alkermes Investigational Site
Hoffman Estates, Illinois, United States
Alkermes Investigational Site
Flowood, Mississippi, United States
Alkermes Investigational Site
St Louis, Missouri, United States
Alkermes Investigational Site
Las Vegas, Nevada, United States
Alkermes Investigational Site
Berlin, New Jersey, United States
Alkermes Investigational Site
Austin, Texas, United States
Alkermes Investigational Site
Garland, Texas, United States
Alkermes Investigational Site
Richardson, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Paliperidone →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 15 Nov 2017
Primary completion: 12 Mar 2019
Completion: 12 Mar 2019
Last update posted: 11 Aug 2020
Registered enrollment: 200
Registry id: NCT03345979

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.